A Multicenter, Open-Label, Single Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Depot Buprenorphine (RBP-6000) in Opioid-Dependent Subjects
Latest Information Update: 01 Mar 2019
At a glance
- Drugs Buprenorphine (Primary)
- Indications Opioid-related disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Indivior
- 22 Feb 2019 Results assessing the effects of a monthly buprenorphine depot subcutaneous injection on QT interval during treatment for opioid use disorder in 1114 subjects pooled from 5 studies (RB-US13-0001, RB-US10-0011, RB-US11-0020, RB-US12-0005, RB-US13-0006) published in the Clinical Pharmacology and Therapeutics
- 29 Dec 2016 New trial record